Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770610 | 0.90 | BACE1 (0.38) | MPLBACE1 | |
| SCHEMBL23770551 | 0.88 | PTPN1 (0.36) | MPLBACE1CTSATRPA1TRPM8 | |
| SCHEMBL23770756 | 0.87 | BACE1 (0.36) | HSD11B1MPLBACE1TRPA1TRPM8 | |
| SCHEMBL23770409 | 0.86 | BACE1 (0.35) | BACE1MYCWDR5KDM4E | |
| SCHEMBL23770675 | 0.84 | TRPA1 (0.35) | BACE1TRPA1 | |
| SCHEMBL23770761 | 0.84 | TRPA1 (0.34) | BACE1TRPA1 | |
| SCHEMBL23770633 | 0.83 | PLA2G7 (0.36) | BACE1MYCWDR5KDM4E | |
| SCHEMBL23770752 | 0.83 | MPL (0.34) | HSD11B1MPL | |
| SCHEMBL23770549 | 0.82 | ABL1 (0.32) | MPL | |
| SCHEMBL23770542 | 0.82 | MPL (0.34) | HSD11B1MPLBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |